Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven gastric adenocarcinoma: uT1,uT2, uT3, Nx, M0~2. No prior chemotherapy~3. Patients of full age, independent of gender ECOG ≤ 2~4. No dissemination of the tumor confirmed by CT of the lung and the abdomen.~5. Signed Consent form of the Patient agreeing to investigations~6. Leucocytes \> 3.000/µl~7. Thrombocytes \> 100.000/µl~8. Creatinine ≤ 1.5mg/dl and or Clearance \> 60 ml/min~9. informed consent of the patient~10. normal ejection-fraction of the heart~Exclusion Criteria:~1. Dissemination of the tumor or non-resectable primary tumor~2. Malignant secondary disease \< 5 years in the past (Exception: in-situ-carcinoma of the cervix and appropriately treated basal cell carcinoma of the skin)~3. Patient not of full age~4. Inflammatory chronic bowel disease~5. Inclusion of the patient in a different study~6. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- positive cytology with HIPEC (Type: EXPERIMENTAL): gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
- positive cytology without HIPEC (Type: NO_INTERVENTION): gastric cancer cytology positive without HIPEC
- negative cytology without HIPEC (Type: NO_INTERVENTION): gastric cancer with negative cytology

Based on this trial design, predict the completion outcome and termination type (if applicable).